Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 2% Improvement Relative Risk Symptomatic case (b) 0% Symptomatic case (c) 5% Symptomatic case (d) 53% Case 51% Case (b) 50% Case (c) 52% Case (d) 70% c19hcq.org McKinnon et al. NCT04341441 WHIP COVID-19 HCQ RCT PEP Favors HCQ Favors control
Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study
McKinnon et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.343, WHIP COVID-19, NCT04341441 (history)
McKinnon et al., Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.343, WHIP COVID-19, NCT04341441
Dec 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
HCQ prophylaxis RCT with 201 weekly HCQ patients, 197 daily HCQ patients, and 200 control patients, concluding the prophylaxis is safe. There were no grade 3 or 4 AEs, SAEs, ER visits, or hospitalizations. There was only 4 confirmed cases, 2 in the placebo arm and one in each HCQ arm. 60% of patients had exposure at baseline.
HCQ 400mg weekly or HCQ 200mg daily after a loading dose of 400mg on day 1.
risk of symptomatic case, 2.5% lower, RR 0.98, p = 1.00, treatment 2 of 365 (0.5%), control 1 of 178 (0.6%), NNT 7219, daily and weekly HCQ combined.
risk of symptomatic case, no change, RR 1.00, p = 1.00, treatment 1 of 178 (0.6%), control 1 of 178 (0.6%), daily HCQ.
risk of symptomatic case, 4.8% lower, RR 0.95, p = 1.00, treatment 1 of 187 (0.5%), control 1 of 178 (0.6%), NNT 3698, weekly HCQ.
risk of symptomatic case, 53.3% lower, RR 0.47, p = 1.00, treatment 0 of 25 (0.0%), control 1 of 178 (0.6%), NNT 178, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), AD patients.
risk of case, 51.2% lower, RR 0.49, p = 0.60, treatment 2 of 365 (0.5%), control 2 of 178 (1.1%), NNT 174, daily and weekly HCQ combined.
risk of case, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 178 (0.6%), control 2 of 178 (1.1%), NNT 178, daily HCQ.
risk of case, 52.4% lower, RR 0.48, p = 0.61, treatment 1 of 187 (0.5%), control 2 of 178 (1.1%), NNT 170, weekly HCQ.
risk of case, 69.5% lower, RR 0.30, p = 1.00, treatment 0 of 25 (0.0%), control 2 of 178 (1.1%), NNT 89, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), AD patients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
McKinnon et al., 23 Dec 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 10 authors, trial NCT04341441 (history) (WHIP COVID-19).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: WHIP COVID-19 Study Journal Pre-proof Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study JE McKinnon , DD Wang , M Zervos , M Saval , L Marshall-Nightengale , P Kilgore , P Pabla , E Szandzik , K Maksimowicz-McKinnon , WW O’Neill PII: DOI: Reference: S1201-9712(21)01243-1 https://doi.org/10.1016/j.ijid.2021.12.343 IJID 5900 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 30 November 2021 15 December 2021 17 December 2021 Please cite this article as: JE McKinnon , DD Wang , M Zervos , M Saval , L Marshall-Nightengale , P Kilgore , P Pabla , E Szandzik , K Maksimowicz-McKinnon , WW O’Neill , Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study, International Journal of Infectious Diseases (2021), doi: https://doi.org/10.1016/j.ijid.2021.12.343 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2021 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) HIGHLIGHTS  Hydroxychloroquine chemoprophylaxis is safe in high-risk populations for COVID-19  No increased cardiovascular risks with hydroxychloroquine chemoprophylaxis  Adverse events were similar between placebo and hydroxychloroquine treatment arms Safety and Tolerability of Hydroxychloroquine in healthcare workers and first responders for the prevention of COVID-19: WHIP COVID-19 Study Running title: WHIP COVID-19 Study McKinnon, JE1; Wang DD2; Zervos, M1; Saval, M2; Marshall-Nightengale, L2,3; Kilgore, P1; Pabla, P4, Szandzik, E4; Maksimowicz-McKinnon, K5; O’Neill, WW2. 1 Infectious Disease, Henry Ford Hospital, Detroit, Michigan 2 Division of Cardiovascular Disease, Center for Structural Heart, Henry Ford Hospital, Detroit, Michigan 3 Public Health Sciences, Henry Ford Hospital, Detroit, Michigan 4 Pharmacy, Henry Ford Hospital, Detroit, Michigan 5 Rheumatology, Henry Ford Hospital, Detroit, Michigan Address for correspondence: John E. McKinnon, MD, MSc Henry Ford Hospital 2799 West Grand Blvd, Clara Ford Pavilion, 432 Detroit, MI 48202 Office: 313-916-8828 Email: jmckinn3@hfhs.org Abbreviations AE; Adverse Event O Degrees Centigrade (Celsius) C: CAP: Community Acquired Pneumonia COVID-19: SARS-CoV-2 clinical coronavirus disease which may be diagnosed by clinical and/or laboratory methods CRL: Case Report Log DDOT: Detroit Department of Transportation EMR: Electronic medical record FDA: U.S. Food and Drug Administration FR: First Responders (police, fire fighters, correctional/law officers, EMT) HCW: Healthcare Workers ICF: Informed Consent Form IRB: Institutional Review Board MS: Medical Students NHW: Nursing Home Workers PI: Principal..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit